BromfenacCompany: Duract, Wyeth-Ayerst Laboratories
Approval Status: Approved July 1997
Treatment for: acute pain
Areas: Neurology & Nervous System; Cancer & Oncology
Bromfenac was cleared for marketing by the FDA on July 15, 1997. This provides an alternative to opioids for the management of acute pain. Bromfenac provides fast relief of acute pain without the side effects of opioid analgesics.
Possible adverse side effects include abdominal pain, headache, nausea, and vomiting.
Bromfenac Drug Information
The Bromfenac drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.